Publications & Posters

All categories

Publications

Posters

All Cell Engagers

AFM11

AFM13

AFM24

AFM26

All years

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

J. Koch, M. Tesar
Transfus Med Hemother 2017; 44:337-350.

link to publication

Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.

Gantke et al.
Protein Eng Des Sel. 2017 Aug 17:1-12. doi: 10.1093/protein/gzx043.

link to publication

AFM26 – Targeting BCMA for NK cell-mediated immunotherapy of multiple myeloma

Gantke et al.
ASH 2017 – AFM26

A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Data from the Dose Escalation Part of the Study

Ansell et al.
ASH 2017 – AFM13

AFM26: A first-in-class, high affinity bispecific NK-cell engager targeting BCMA to treat multiple myeloma

Gantke et al.
EACR-AACR-SIC 2017 Special Conference

High affinity bispecific EGFR/CD16A antibodies specifically recruit NK-cells to target EGFR-expressing tumors

Kluge et al.
EACR-AACR-SIC 2017 Special Conference

AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma

Gantke et al.
ASCO 2017 AFM26

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

Ellwanger et al.
Front Oncol. 2017 May 19;7:100. doi: 10.3389/fonc.2017.00100. eCollection 2017.

link to publication

EGFR/CD16A TandAbs are efficacious NK-cell engagers with favorable biological properties which potently kill EGFR+ tumors with and without Ras mutation

Kluge et al.
AACR 2017 – AFM24

Identification of antibodies against a novel tumor-associated MHC/peptide-target and generation of highly specific and potent HLA-A*02MMP1-003/CD3 TandAbs

Weinschenk et al.
AACR 2017 – MHC

1
2
3
4
5
6